Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 125
Filter
1.
Proc Natl Acad Sci U S A ; 119(26): e2121987119, 2022 06 28.
Article in English | MEDLINE | ID: mdl-35749365

ABSTRACT

Mechanisms of defense against ferroptosis (an iron-dependent form of cell death induced by lipid peroxidation) in cellular organelles remain poorly understood, hindering our ability to target ferroptosis in disease treatment. In this study, metabolomic analyses revealed that treatment of cancer cells with glutathione peroxidase 4 (GPX4) inhibitors results in intracellular glycerol-3-phosphate (G3P) depletion. We further showed that supplementation of cancer cells with G3P attenuates ferroptosis induced by GPX4 inhibitors in a G3P dehydrogenase 2 (GPD2)-dependent manner; GPD2 deletion sensitizes cancer cells to GPX4 inhibition-induced mitochondrial lipid peroxidation and ferroptosis, and combined deletion of GPX4 and GPD2 synergistically suppresses tumor growth by inducing ferroptosis in vivo. Mechanistically, inner mitochondrial membrane-localized GPD2 couples G3P oxidation with ubiquinone reduction to ubiquinol, which acts as a radical-trapping antioxidant to suppress ferroptosis in mitochondria. Taken together, these results reveal that GPD2 participates in ferroptosis defense in mitochondria by generating ubiquinol.


Subject(s)
Ferroptosis , Glycerolphosphate Dehydrogenase , Lipid Peroxidation , Mitochondria , Mitochondrial Proteins , Neoplasms , Cell Line, Tumor , Ferroptosis/genetics , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/genetics , Glycerolphosphate Dehydrogenase/metabolism , Humans , Lipid Peroxidation/genetics , Mitochondria/enzymology , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Neoplasms/enzymology , Neoplasms/pathology , Phospholipid Hydroperoxide Glutathione Peroxidase/metabolism
2.
Proc Natl Acad Sci U S A ; 119(10): e2122287119, 2022 03 08.
Article in English | MEDLINE | ID: mdl-35238637

ABSTRACT

SignificanceMetformin is the most commonly prescribed drug for the treatment of type 2 diabetes mellitus, yet the mechanism by which it lowers plasma glucose concentrations has remained elusive. Most studies to date have attributed metformin's glucose-lowering effects to inhibition of complex I activity. Contrary to this hypothesis, we show that inhibition of complex I activity in vitro and in vivo does not reduce plasma glucose concentrations or inhibit hepatic gluconeogenesis. We go on to show that metformin, and the related guanides/biguanides, phenformin and galegine, inhibit complex IV activity at clinically relevant concentrations, which, in turn, results in inhibition of glycerol-3-phosphate dehydrogenase activity, increased cytosolic redox, and selective inhibition of glycerol-derived hepatic gluconeogenesis both in vitro and in vivo.


Subject(s)
Electron Transport Complex IV/antagonists & inhibitors , Gluconeogenesis , Guanidines/pharmacology , Hypoglycemic Agents/pharmacology , Metformin/pharmacology , Phenformin/pharmacology , Animals , Glucose/metabolism , Glycerol/metabolism , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Liver/drug effects , Liver/metabolism , Oxidation-Reduction , Pyridines/pharmacology
3.
Diabetes ; 70(7): 1575-1580, 2021 07.
Article in English | MEDLINE | ID: mdl-33849997

ABSTRACT

Mitochondrial glycerol phosphate dehydrogenase (mGPD) is the rate-limiting enzyme of the glycerol phosphate redox shuttle. It was recently claimed that metformin, a first-line drug used for the treatment of type 2 diabetes, inhibits liver mGPD 30-50%, suppressing gluconeogenesis through a redox mechanism. Various factors cast doubt on this idea. Total-body knockout of mGPD in mice has adverse effects in several tissues where the mGPD level is high but has little or no effect in liver, where the mGPD level is the lowest of 10 tissues. Metformin has beneficial effects in humans in tissues with high levels of mGPD, such as pancreatic ß-cells, where the mGPD level is much higher than that in liver. Insulin secretion in mGPD knockout mouse ß-cells is normal because, like liver, ß-cells possess the malate aspartate redox shuttle whose redox action is redundant to the glycerol phosphate shuttle. For these and other reasons, we used four different enzyme assays to reassess whether metformin inhibited mGPD. Metformin did not inhibit mGPD in homogenates or mitochondria from insulin cells or liver cells. If metformin actually inhibited mGPD, adverse effects in tissues where the level of mGPD is much higher than that in the liver could prevent the use of metformin as a diabetes medicine.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Metformin/pharmacology , Mitochondria/enzymology , Animals , Gluconeogenesis/drug effects , Humans , Male , Metformin/therapeutic use , Mice , Mice, Inbred BALB C , NAD/metabolism , Oxidation-Reduction , Phenformin/pharmacology , Rats
4.
Bull Exp Biol Med ; 168(4): 470-473, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32146623

ABSTRACT

Combined antituberculosis substances induced a dose-dependent changes in activity of dehydrogenases and hydrolases in rat lymphocytes. The main toxic effect of the substances was related to inhibition of mitochondrial dehydrogenases (succinate dehydrogenase and α-glycerol phosphate dehydrogenase) usually followed by suppression of activity of hydrolytic enzymes (acid phosphatase and non-specific esterase). Opposite changes in lactate dehydrogenase activity reflected specific features of intoxication.


Subject(s)
Antitubercular Agents/toxicity , Ethambutol/toxicity , Fluoroquinolones/toxicity , Isoniazid/toxicity , Lymphocytes/drug effects , Prothionamide/toxicity , Pyrazinamide/toxicity , Rifampin/toxicity , Acid Phosphatase/genetics , Acid Phosphatase/metabolism , Administration, Oral , Animals , Animals, Outbred Strains , Drug Combinations , Esterases/genetics , Esterases/metabolism , Gene Expression/drug effects , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/genetics , Glycerolphosphate Dehydrogenase/metabolism , L-Lactate Dehydrogenase/genetics , L-Lactate Dehydrogenase/metabolism , Lymphocytes/cytology , Lymphocytes/enzymology , Male , Primary Cell Culture , Rats , Succinate Dehydrogenase/antagonists & inhibitors , Succinate Dehydrogenase/genetics , Succinate Dehydrogenase/metabolism
5.
Pestic Biochem Physiol ; 135: 41-46, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28043329

ABSTRACT

Insects pollinate 75% of crops used for human consumption. Over the last decade, a substantial reduction in the abundance of pollinating insects has been recorded and recognized as a severe matter for food supply security. Many of the important food crops destined for human consumption are grown in greenhouses. A unique feature of greenhouse agriculture is the extensive use of fungicides to curb multiple fungal infections. The most widely used pollinating insects in greenhouses are commercially reared bumblebees. However, there is no data regarding the toxicity of fungicides to bumblebee mitochondria. To fill this gap in knowledge, we examined the effects of 16 widely used fungicides on the energetics of the flight muscles mitochondria of Bombus terrestris. We found that diniconazole and fludioxonil uncoupled the respiration of mitochondria; dithianon and difenoconazole inhibited it. By analyzing the action of these inhibitors on mitochondrial respiration and generation of reactive oxygen species, we concluded that difenoconazole inhibited electron transport at the level of Complex I and glycerol-3-phosphate dehydrogenase. Dithianon strongly inhibited succinate dehydrogenase and glycerol-3-phosphate dehydrogenase. It also strongly inhibited mitochondrial oxidation of NAD-linked substrates or glycerol 3-phosphate, but it had no effect on the enzymatic activity of Complex I. It may be suggested that dithianon inhibits electron transport downstream of Complex I, likely at multiply sites.


Subject(s)
Bees , Fungicides, Industrial/toxicity , Mitochondria, Muscle/drug effects , Animals , Electron Transport/drug effects , Electron Transport Complex I/metabolism , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Glycerophosphates/metabolism , Insect Proteins/antagonists & inhibitors , Insect Proteins/metabolism , Male , Membrane Potential, Mitochondrial/drug effects , Mitochondria, Muscle/metabolism , NADH Dehydrogenase/antagonists & inhibitors , NADH Dehydrogenase/metabolism , Reactive Oxygen Species/metabolism , Succinate Dehydrogenase/antagonists & inhibitors , Succinate Dehydrogenase/metabolism
6.
J Endocrinol ; 228(3): R97-106, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26743209

ABSTRACT

Metformin is a first-line oral anti-diabetic agent that has been used clinically to treat patients with type 2 diabetes for over 60 years. Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year. Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling. However, its mechanism of action remains partially understood and controversial, especially in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation. In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose production and the mechanism related to the improvement of insulin signaling.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hyperglycemia/drug therapy , Hypoglycemic Agents , Metformin/pharmacology , Metformin/therapeutic use , AMP-Activated Protein Kinases/physiology , Enzyme Activation/drug effects , Enzyme Activation/physiology , Enzyme Inhibitors , Gastrointestinal Microbiome/drug effects , Gluconeogenesis/drug effects , Glucose/metabolism , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Humans , Insulin/metabolism , Liver/metabolism , Signal Transduction/drug effects
7.
Bioorg Med Chem Lett ; 25(17): 3564-8, 2015 09 01.
Article in English | MEDLINE | ID: mdl-26169126

ABSTRACT

The enzyme glycerol-3-phosphate dehydrogenase (G3PDH) from Leishmania species is considered as an attractive target to design new antileishmanial drugs and a previous in silico study reported on the importance of chalcones to achieve its inhibition. Here, we report the identification of a synthetic chalcone in our in vitro assays with promastigote cells from Leishmania amazonensis, its biological activity in animal models, and docking followed by molecular dynamics simulation to investigate the molecular interactions and structural patterns that are crucial to achieve the inhibition complex between this compound and G3PDH. A molecular fragment of this natural product derivative can provide new inhibitors with increased potency and selectivity.


Subject(s)
Antiprotozoal Agents/chemistry , Antiprotozoal Agents/pharmacology , Chalcones/chemistry , Chalcones/pharmacology , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Leishmania/enzymology , Animals , Glycerolphosphate Dehydrogenase/metabolism , Leishmania/drug effects , Leishmaniasis/drug therapy , Leishmaniasis/parasitology , Macrophages/drug effects , Mice , Molecular Docking Simulation
8.
PLoS One ; 10(3): e0119531, 2015.
Article in English | MEDLINE | ID: mdl-25803639

ABSTRACT

Pseudomonas aeruginosa biofilm is commonly associated with chronic wound infection. A FDA approved wireless electroceutical dressing (WED), which in the presence of conductive wound exudate gets activated to generate electric field (0.3-0.9V), was investigated for its anti-biofilm properties. Growth of pathogenic P. aeruginosa strain PAO1 in LB media was markedly arrested in the presence of the WED. Scanning electron microscopy demonstrated that WED markedly disrupted biofilm integrity in a setting where silver dressing was ineffective. Biofilm thickness and number of live bacterial cells were decreased in the presence of WED. Quorum sensing genes lasR and rhlR and activity of electric field sensitive enzyme, glycerol-3-phosphate dehydrogenase was also repressed by WED. This work provides first electron paramagnetic resonance spectroscopy evidence demonstrating that WED serves as a spontaneous source of reactive oxygen species. Redox-sensitive multidrug efflux systems mexAB and mexEF were repressed by WED. Taken together, these observations provide first evidence supporting the anti-biofilm properties of WED.


Subject(s)
Bandages , Biofilms/drug effects , Electric Stimulation Therapy/methods , Pseudomonas aeruginosa/drug effects , Silver/administration & dosage , Wound Infection/therapy , Zinc/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Biofilms/growth & development , Electric Stimulation Therapy/instrumentation , Electron Spin Resonance Spectroscopy , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Oxidation-Reduction , Pseudomonas aeruginosa/physiology , Quorum Sensing , Silver/chemistry , Wound Infection/metabolism , Zinc/chemistry
9.
Mem. Inst. Oswaldo Cruz ; 110(1): 75-85, 03/02/2015. graf
Article in English | LILACS | ID: lil-741624

ABSTRACT

In our previous study, we have found that 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-ylamine (BAY 41-2272), a guanylate cyclase agonist, activates human monocytes and the THP-1 cell line to produce the superoxide anion, increasing in vitro microbicidal activity, suggesting that this drug can be used to modulate immune functioning in primary immunodeficiency patients. In the present work, we investigated the potential of the in vivo administration of BAY 41-2272 for the treatment of Candida albicans and Staphylococcus aureus infections introduced via intraperitoneal and subcutaneous inoculation. We found that intraperitoneal treatment with BAY 41-2272 markedly increased macrophage-dependent cell influx to the peritoneum in addition to macrophage functions, such as spreading, zymosan particle phagocytosis and nitric oxide and phorbol myristate acetate-stimulated hydrogen peroxide production. Treatment with BAY 41-2272 was highly effective in reducing the death rate due to intraperitoneal inoculation of C. albicans, but not S. aureus. However, we found that in vitro stimulation of peritoneal macrophages with BAY 41-2272 markedly increased microbicidal activities against both pathogens. Our results show that the prevention of death by the treatment of C. albicans-infected mice with BAY 41-2272 might occur primarily by the modulation of the host immune response through macrophage activation. .


Subject(s)
Animals , Mice , Adipocytes, White/metabolism , Ananas/chemistry , Dietary Supplements , Fruit/chemistry , Hypoglycemic Agents/isolation & purification , Industrial Waste/analysis , Plant Extracts/isolation & purification , Adipogenesis , Adipocytes, White/cytology , Antioxidants/chemistry , Antioxidants/economics , Antioxidants/isolation & purification , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/economics , Enzyme Inhibitors/isolation & purification , Food-Processing Industry/economics , Glycosylation , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Glycoside Hydrolase Inhibitors/chemistry , Glycoside Hydrolase Inhibitors/economics , Glycoside Hydrolase Inhibitors/isolation & purification , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/economics , India , Industrial Waste/economics , Lipotropic Agents/chemistry , Lipotropic Agents/economics , Lipotropic Agents/isolation & purification , Plant Extracts/chemistry , Plant Extracts/economics , Solvents/chemistry , alpha-Amylases/antagonists & inhibitors , alpha-Amylases/metabolism
11.
Molecules ; 19(10): 16656-71, 2014 Oct 15.
Article in English | MEDLINE | ID: mdl-25322285

ABSTRACT

Obesity and its related disorders have become leading metabolic diseases. In the present study, we used 3T3-L1 adipocytes to investigate the anti-obesity activity of hispidin and two related compounds that were isolated from Alpinia zerumbet (alpinia) rhizomes. The results showed that hispidin, dihydro-5,6-dehydrokawain (DDK), and 5,6-dehydrokawain (DK) have promising anti-obesity properties. In particular, all three compounds significantly increased intracellular cyclic adenosine monophosphate (cAMP) concentrations by 81.2% ± 0.06%, 67.0% ± 1.62%, and 56.9% ± 0.19%, respectively. Hispidin also stimulated glycerol release by 276.4% ± 0.8% and inhibited lipid accumulation by 47.8% ± 0.16%. Hispidin and DDK decreased intracellular triglyceride content by 79.5% ± 1.37% and 70.2% ± 1.4%, respectively, and all three compounds inhibited glycerol-3-phosphate dehydrogenase (GPDH) and pancreatic lipase, with hispidin and DDK being the most potent inhibitors. Finally, none of the three compounds reduced 3T3-L1 adipocyte viability. These results highlight the potential for developing hispidin and its derivatives as anti-obesity compounds.


Subject(s)
Adipocytes/drug effects , Alpinia/chemistry , Anti-Obesity Agents/pharmacology , Obesity/drug therapy , Plant Extracts/pharmacology , Pyrones/pharmacology , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/metabolism , Adipogenesis/drug effects , Animals , Cell Survival/drug effects , Cyclic AMP/metabolism , Glycerol/metabolism , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Lipase/antagonists & inhibitors , Lipase/metabolism , Lipids/analysis , Mice , Triglycerides/metabolism
12.
Cell Metab ; 20(2): 197-9, 2014 Aug 05.
Article in English | MEDLINE | ID: mdl-25100057

ABSTRACT

Metformin is the most widely prescribed drug to lower glucose in type II diabetics, yet its mechanism of action remains controversial. A new study reveals that metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase, triggering reduction of the cytosolic NADH/NAD(+) pool and impaired utilization of redox-dependent substrates for gluconeogenesis (Madiraju et al., 2014).


Subject(s)
Gluconeogenesis/drug effects , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Metformin/pharmacology , Mitochondria/enzymology , Animals , Humans , Male
13.
Int J Biochem Cell Biol ; 53: 409-13, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24953557

ABSTRACT

α-Tocopheryl succinate (TOS), a redox-silent analogue of vitamin E, suppresses cell growth in a number of clinical and experimental cancers, inhibits mitochondrial succinate dehydrogenase (SDH) and activates reactive oxygen species (ROS) generation. The aim of this study was to test whether TOS also inhibits glycerol-3-phosphate dehydrogenase (mGPDH), another flavoprotein-dependent enzyme of the mitochondrial respiratory chain because there are differences between electron transfer pathway from SDH and mGPDH to coenzyme Q pool. For our experiments brown adipose tissue mitochondria with high expression of mGPDH were used. Our data showed that inhibition of glycerol-3-phosphate (GP)-dependent oxygen consumption by TOS was more pronounced than the succinate (SUC)-dependent one (50% inhibition was reached at 10 µmol/l TOS vs. 80 µmol/l TOS, respectively). A comparison of the inhibitory effect of TOS on GP-oxidase, GP-cytochrome c oxidoreductase and GP-dehydrogenase activities showed that TOS directly interacts with the dehydrogenase. After TOS application the GP-dependent generation of ROS was highly depressed. It may thus be concluded that TOS-induced inhibition of mGPDH is more pronounced than TOS-induced inhibition of SDH and that the inhibitory effect of TOS for both substrates is exerted at different locations of the particular dehydrogenases. Our data indicate that the inhibition of mGPDH activity could also play a role in TOS-induced growth suppression in neoplastic cells.


Subject(s)
Carcinogenesis/genetics , Glycerolphosphate Dehydrogenase/biosynthesis , Mitochondria/enzymology , alpha-Tocopherol/administration & dosage , Adipose Tissue, Brown/enzymology , Animals , Cricetinae , Gene Expression Regulation, Neoplastic/drug effects , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Humans , Mitochondria/drug effects , Neoplasms/drug therapy , Neoplasms/enzymology , Oxygen Consumption/drug effects , Reactive Oxygen Species/metabolism
14.
Nature ; 510(7506): 542-6, 2014 Jun 26.
Article in English | MEDLINE | ID: mdl-24847880

ABSTRACT

Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia. For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin's blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.


Subject(s)
Gluconeogenesis/drug effects , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Metformin/pharmacology , Mitochondria/enzymology , Animals , Blood Glucose/analysis , Blood Glucose/biosynthesis , Cells, Cultured , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/metabolism , Glycerolphosphate Dehydrogenase/deficiency , Glycerolphosphate Dehydrogenase/genetics , Glycerolphosphate Dehydrogenase/metabolism , Humans , Hypoglycemic Agents/pharmacology , Insulin/metabolism , Insulin Secretion , Lactic Acid/metabolism , Liver/drug effects , Liver/metabolism , Male , Mice, Knockout , Oxidation-Reduction/drug effects , Rats , Rats, Sprague-Dawley
15.
J Sci Food Agric ; 94(5): 943-50, 2014 Mar 30.
Article in English | MEDLINE | ID: mdl-23929507

ABSTRACT

BACKGROUND: Rapid urbanisation and nutritional transition is fuelling the increased global incidence of type 2 diabetes. Pineapple fruit residue was explored for its nutraceutical properties as an alternative or adjunct to currently available treatment regime. Ethyl acetate and methanolic extracts of pineapple fruit residue were evaluated for anti-diabetic activity in cell free and cell based systems. Specifically, we assessed: (1) antioxidant potential, (2) anti-glycation potential, (3) carbohydrate digestive enzyme inhibition, and (4) lipid accumulation and glycerol-3-phosphate dehydrogenase activity in differentiating 3T3-L1 cells. RESULTS: The active components in the ethyl acetate and methanolic extracts were identified as sinapic acid, daucosterol, 2-methylpropanoate, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, methyl 2-methylbutanoate and triterpenoid ergosterol using DART/HRMS and ESI/HRMS. Micronutrient analysis revealed the presence of magnesium, potassium and calcium. Adipogenic potential, anti-glycation property of the ethyl acetate extract, and DNA damage protection capacity of the methanolic extract are promising. CONCLUSION: Results from this study clearly indicate that pineapple fruit residue could be utilised as a nutraceutical against diabetes and related complications.


Subject(s)
Adipocytes, White/metabolism , Ananas/chemistry , Dietary Supplements , Fruit/chemistry , Hypoglycemic Agents/isolation & purification , Industrial Waste/analysis , Plant Extracts/isolation & purification , 3T3-L1 Cells , Adipocytes, White/cytology , Adipogenesis , Animals , Antioxidants/chemistry , Antioxidants/economics , Antioxidants/isolation & purification , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/economics , Enzyme Inhibitors/isolation & purification , Food-Processing Industry/economics , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Glycoside Hydrolase Inhibitors/chemistry , Glycoside Hydrolase Inhibitors/economics , Glycoside Hydrolase Inhibitors/isolation & purification , Glycosylation , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/economics , India , Industrial Waste/economics , Lipotropic Agents/chemistry , Lipotropic Agents/economics , Lipotropic Agents/isolation & purification , Mice , Plant Extracts/chemistry , Plant Extracts/economics , Solvents/chemistry , alpha-Amylases/antagonists & inhibitors , alpha-Amylases/metabolism
16.
Future Med Chem ; 5(15): 1777-99, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24144413

ABSTRACT

BACKGROUND: Leishmaniasis is a collection of chronic diseases caused by protozoa of the genus Leishmania. Current antileishmanial chemotherapeutics have demonstrated adverse side effects and therefore R&D into new safer alternative treatments are needed. METHODS: A molecular docking analysis has been carried out to assess possible Leishmania biochemical targets of antiparasitic alkaloids. A total of 209 antiparasitic alkaloids were docked with 24 Leishmania protein targets. RESULTS: The strongest docking alkaloid ligands were flinderoles A and B and juliflorine with Leishmania major methionyl-tRNA synthetase; juliflorine, juliprosine, prosopilosidine and prosopilosine with Leishmania mexicana glycerol-3-phosphate dehydrogenase; and ancistrogriffithine A with L. major N-myristoyl transferase. CONCLUSION: This molecular docking study has provided evidence for what classes and structural types of alkaloids may be targeting specific Leishmania protein targets.


Subject(s)
Alkaloids/chemistry , Antiprotozoal Agents/chemistry , Leishmania major/enzymology , Leishmania mexicana/enzymology , Protozoan Proteins/antagonists & inhibitors , Alkaloids/pharmacology , Antiprotozoal Agents/pharmacology , Binding Sites , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Leishmania major/drug effects , Leishmania mexicana/drug effects , Methionine-tRNA Ligase/antagonists & inhibitors , Methionine-tRNA Ligase/metabolism , Molecular Docking Simulation , Protein Structure, Tertiary , Protozoan Proteins/metabolism , Static Electricity
17.
Cell Biol Int ; 37(9): 1003-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23804196

ABSTRACT

Intercellular signalling communication between adipose and muscle tissue has been investigated. To test the effect of muscle cells on adipogenic gene expression, we utilised an in vitro co-culture system, in which fat (3T3-L1) and muscle (L-6) cells were physically separated but chemically exposed each other via insert with 0.4 µm porous membrane. When 3T3-L1 and L-6 cells reached at 80 and 40% confluence, respectively in separate wells, L-6 cells grown in insert were transferred onto 6-well plates where 3T3-L1 cells were being grown. When both cells were fully differentiated in co-culture plates, morphology of 3T3-L1 was examined by staining with Oil-red-O. Activity of glycerol-3-phosphate dehydrogenase (GPDH) and adipogenic gene expression including lipoprotein lipase (LPL), adipsin, GPDH, peroxisome proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein (C/EBPα) were analysed. The presence of muscle cells during preadipocyte differentiation inhibited (P < 0.05) lipogenesis by suppressing lipogenic gene expression including LPL, adipsin and GPDH. Furthermore, GPDH activity was also decreased (P < 0.05) in 3T3-L1 cells by the presence of L-6 cells. These results suggest that presence of muscle cells suppresses adipogenic differentiation by inhibiting the adipogenic gene expression and GPDH activity in the muscle and fat cell co-culture system.


Subject(s)
Adipogenesis/genetics , Cell Communication/genetics , Gene Expression Regulation/genetics , Lipogenesis/genetics , Muscle Fibers, Skeletal/metabolism , 3T3-L1 Cells , Animals , CCAAT-Enhancer-Binding Proteins/genetics , CCAAT-Enhancer-Binding Proteins/metabolism , Cell Differentiation , Coculture Techniques , Complement Factor D/antagonists & inhibitors , Complement Factor D/genetics , Complement Factor D/metabolism , Diffusion Chambers, Culture , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/genetics , Glycerolphosphate Dehydrogenase/metabolism , Lipoprotein Lipase/antagonists & inhibitors , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Mice , Muscle Fibers, Skeletal/cytology , PPAR gamma/genetics , PPAR gamma/metabolism , Signal Transduction
18.
J Sci Food Agric ; 93(3): 485-90, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22821258

ABSTRACT

BACKGROUND: Kefir, a traditional fermented milk composed of microbial symbionts, is reported to have various health benefits such as anti-tumour, anti-inflammatory, anti-neoplastic and pro-digestive effects. In this study, to elucidate the effects of kefir on adipocyte differentiation and lipid accumulation, three fractions were prepared from kefir culture broth. The inhibitory effects of kefir liquid culture broth fraction (Fr-1), soluble fraction (Fr-2) and insoluble fraction (Fr-3), prepared by sonication of kefir solid culture broth, on adipocyte differentiation in 3T3-L1 preadipocytes were examined. RESULTS: Fr-3 (0.1 mg mL(-1)) significantly decreased lipid accumulation and glycerol-3-phosphate dehydrogenase (GPDH) activity by 60 and 68% respectively without affecting cell viability. In addition, Fr-3 treatment down-regulated the mRNA expression of adipogenic transcription factors including C/EBPα (32%), PPARγ (46%) and SREBP-1c (34%) during adipocyte differentiation compared with untreated control cells. The mRNA expression of adipocyte-specific genes (aP2, FAS and ACC) was also clearly decreased. CONCLUSION: The results suggest that the insoluble fraction of kefir (Fr-3) mediates anti-adipogenic effects through the inhibition of adipocyte differentiation, partly via suppression of the C/EBPα-, SREBP-1c- and PPARγ-dependent pathways.


Subject(s)
Adipocytes/cytology , Adipogenesis/genetics , Cell Differentiation/physiology , Cultured Milk Products/physiology , Transcription Factors/genetics , 3T3-L1 Cells , Animals , CCAAT-Enhancer-Binding Protein-alpha/antagonists & inhibitors , CCAAT-Enhancer-Binding Protein-alpha/genetics , Cultured Milk Products/chemistry , Down-Regulation , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Mice , PPAR gamma/antagonists & inhibitors , PPAR gamma/genetics , RNA, Messenger/genetics , Solubility , Sterol Regulatory Element Binding Protein 1/antagonists & inhibitors , Sterol Regulatory Element Binding Protein 1/genetics
19.
Cell Rep ; 2(5): 1300-15, 2012 Nov 29.
Article in English | MEDLINE | ID: mdl-23168256

ABSTRACT

Mitochondria-originating reactive oxygen species (ROS) control T cell receptor (TCR)-induced gene expression. Here, we show that TCR-triggered activation of ADP-dependent glucokinase (ADPGK), an alternative, glycolytic enzyme typical for Archaea, mediates generation of the oxidative signal. We also show that ADPGK is localized in the endoplasmic reticulum and suggest that its active site protrudes toward the cytosol. The ADPGK-driven increase in glycolytic metabolism coincides with TCR-induced glucose uptake, downregulation of mitochondrial respiration, and deviation of glycolysis toward mitochondrial glycerol-3-phosphate dehydrogenase(GPD) shuttle; i.e., a metabolic shift to aerobic glycolysis similar to the Warburg effect. The activation of respiratory-chain-associated GPD2 results in hyperreduction of ubiquinone and ROS release from mitochondria. In parallel, mitochondrial bioenergetics and ultrastructure are altered. Downregulation of ADPGK or GPD2 abundance inhibits oxidative signal generation and induction of NF-κB-dependent gene expression, whereas overexpression of ADPGK potentiates them.


Subject(s)
Glucokinase/metabolism , Mitochondria/metabolism , Reactive Oxygen Species/metabolism , T-Lymphocytes/metabolism , Amino Acid Sequence , Archaea/enzymology , Down-Regulation , Endoplasmic Reticulum/enzymology , Glucokinase/antagonists & inhibitors , Glucokinase/chemistry , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/genetics , Glycerolphosphate Dehydrogenase/metabolism , Glycolysis , Humans , Jurkat Cells , Lymphocyte Activation , Mitochondria/enzymology , Mitochondria/ultrastructure , Molecular Sequence Data , NF-kappa B/metabolism , Protein Structure, Secondary , RNA Interference , RNA, Small Interfering/metabolism , Receptors, Antigen, T-Cell/metabolism , Sequence Alignment , T-Lymphocytes/immunology , Ubiquinone/metabolism
20.
Chem Pharm Bull (Tokyo) ; 60(1): 129-36, 2012.
Article in English | MEDLINE | ID: mdl-22223384

ABSTRACT

Obesity is a serious health problem worldwide. We investigated the anti-obesity effect of the flower of Albizia julibrissin DURAZZ. (Leguminosae). A 90% EtOH extract of the flower inhibited adipogenesis in 3T3-L1 preadipocytes, as well as the activity of glycerol-3-phosphate dehydrogenase (GPDH) activity. New flavonol acylglycosides (1-4) and eighteen known compounds (5-22) were isolated by bioassay-directed fractionation. These new glycosides were elucidated to be 3″-(E)-p-coumaroylquercitrin (1), 3″-(E)-feruloylquercitrin (2), 3″-(E)-cinnamoylquercitrin (3), and 2″-(E)-cinnamoylquercitrin (4) on the basis of spectroscopic and chemical analysis. These compounds inhibited adipogenesis in 3T3-L1 preadipocytes. In particular, 2 exhibited potent inhibitory effects on triglyceride accumulation. Furthermore, GPDH activity was inhibited by 2. Additionally, 2 inhibited glucose uptake in 3T3-L1 adipocytes. These results indicate that the 90% EtOH extract and compounds isolated from the flower of A. julibrissin inhibit adipogenesis in 3T3-L1 preadipocytes and may have anti-obesity effect through the inhibition of preadipocyte differentiation.


Subject(s)
Albizzia/chemistry , Anti-Obesity Agents/chemistry , Flavonols/chemistry , Glycosides/chemistry , Lipid Metabolism/drug effects , 3T3-L1 Cells , Adipogenesis/drug effects , Animals , Anti-Obesity Agents/isolation & purification , Anti-Obesity Agents/pharmacology , Cell Differentiation/drug effects , Flowers/chemistry , Glycerolphosphate Dehydrogenase/antagonists & inhibitors , Glycerolphosphate Dehydrogenase/metabolism , Glycosides/isolation & purification , Glycosides/pharmacology , Mice , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...